Petra Denig

List of Publications by Year in descending order

150 papers	2,995 citations	201575 27 h-index	254106 43 g-index
153 all docs	153 docs citations	153 times ranked	3486 citing authors

#	Article	IF	Citations
1	How physicians choose drugs. Social Science and Medicine, 1988, 27, 1381-1386.	1.8	126
2	Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. Journal of Psychosomatic Research, 2014, 76, 134-138.	1.2	115
3	Review: Relation Between Quality-of-Care Indicators for Diabetes and Patient Outcomes: A Systematic Literature Review. Medical Care Research and Review, 2011, 68, 263-289.	1.0	93
4	Primary Prevention of Major Cardiovascular and Cerebrovascular Events with Statins in Diabetic Patients. Drugs, 2012, 72, 2365-2373.	4.9	89
5	Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. British Journal of Clinical Pharmacology, 2019, 85, 1507-1515.	1.1	89
6	Evaluating an Educational Intervention to Improve the Treatment of Asthma in Four European Countries. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1254-1262.	2.5	76
7	Computerized Extraction of Information on the Quality of Diabetes Care from Free Text in Electronic Patient Records of General Practitioners. Journal of the American Medical Informatics Association: JAMIA, 2007, 14, 349-354.	2.2	76
8	Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiology and Drug Safety, 2009, 18, 159-165.	0.9	69
9	Physician, Organizational, and Patient Factors Associated With Suboptimal Blood Pressure Management in Type 2 Diabetic Patients in Primary Care. Diabetes Care, 2004, 27, 123-128.	4.3	55
10	Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial. BMJ, The, 2014, 349, g5651-g5651.	3.0	55
11	Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study. BMC Family Practice, 2009, 10, 24.	2.9	50
12	A Longitudinal Study Examining Adherence to Guidelines in Diabetes Care According to Different Definitions of Adequacy and Timeliness. PLoS ONE, 2011, 6, e24278.	1.1	49
13	Trends in polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States. PLoS ONE, 2019, 14, e0214240.	1.1	47
14	Identifying general practice patients diagnosed with asthma and their exacerbation episodes from prescribing data. European Journal of Clinical Pharmacology, 2002, 57, 819-825.	0.8	46
15	Towards understanding treatment preferences of hospital physicians. Social Science and Medicine, 1993, 36, 915-924.	1.8	43
16	Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis. PLoS ONE, 2014, 9, e111247.	1.1	42
17	Improving drug treatment in general practice. Journal of Clinical Epidemiology, 2000, 53, 762-772.	2.4	41
18	Therapeutic decision making of physicians. Pharmaceutisch Weekblad Scientific Edition, 1992, 14, 9-15.	0.9	39

#	Article	IF	Citations
19	Scope and nature of prescribing decisions made by general practitioners. Quality and Safety in Health Care, 2002, 11, 137-143.	2.5	37
20	Trends in polypharmacy and potentially inappropriate medication (PIM) in older and middleâ€aged people treated for diabetes. British Journal of Clinical Pharmacology, 2021, 87, 2807-2817.	1.1	35
21	Do Physicians Take Cost Into Account When Making Prescribing Decisions?. Pharmacoeconomics, 1995, 8, 282-290.	1.7	34
22	The Ethics of Deprescribing in Older Adults. Journal of Bioethical Inquiry, 2016, 13, 581-590.	0.9	34
23	Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study. Drug Safety, 2020, 43, 489-495.	1.4	34
24	Impact of a Drug Bulletin on the Knowledge, Perception of Drug Utility, and Prescribing Behavior of Physicians. DICP: the Annals of Pharmacotherapy, 1990, 24, 87-93.	0.2	33
25	Prescribing quality indicators of type 2 diabetes mellitus ambulatory care. Quality and Safety in Health Care, 2008, 17, 318-323.	2.5	31
26	Outcome prioritisation tool for medication review in older patients with multimorbidity: a pilot study in general practice. British Journal of General Practice, 2017, 67, e501-e506.	0.7	30
27	Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review. Diabetic Medicine, 2015, 32, 853-864.	1.2	29
28	Communication on Safety of Medicines in Europe: Current Practices and General Practitionersâ€™ Awareness and Preferences. Drug Safety, 2017, 40, 729-742.	1.4	29
29	Relationship between guideline treatment and health-related quality of life in asthma. European Respiratory Journal, 2004, 23, 718-722.	3.1	28
30	Determinants for the adoption of angiotensin II receptor blockers by general practitioners. Social Science and Medicine, 2006, 63, 2890-2898.	1.8	28
31	Cross-Sectional Versus Sequential Quality Indicators of Risk Factor Management in Patients with Type 2 Diabetes. Medical Care, 2008, 46, 133-141.	1.1	28
32	Physicians' views on joint treatment guidelines for primary and secondary care. International Journal for Quality in Health Care, 2004, 16, 229-236.	0.9	27
33	Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study. Drug Safety, 2013, 36, 1105-1115.	1.4	27
34	The value of clinical judgement analysis for improving the quality of doctorsâ€™ prescribing decisions. Medical Education, 2002, 36, 770-780.	1.1	26
35	An educational programme for peer review groups to improve treatment of chronic heart failure and diabetes mellitus type 2 in general practice. Journal of Evaluation in Clinical Practice, 2006, 12, 613-621.	0.9	26
36	Validity of performance indicators for assessing prescribing quality: the case of asthma. European Journal of Clinical Pharmacology, 2004, 59, 833-840.	0.8	25

#	Article	IF	Citations
37	Medication Adherence Affects Treatment Modifications in Patients With Type 2 Diabetes. Clinical Therapeutics, 2011, 33, 121-134.	1.1	25
38	Differential Effects of Comorbidity on Antihypertensive and Glucose-Regulating Treatment in Diabetes Mellitus â€“ A Cohort Study. PLoS ONE, 2012, 7, e38707.	1.1	25
39	Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire. Drug Safety, 2013, 36, 765-777.	1.4	25
40	Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients. Drug Safety, 2018, 41, 697-712.	1.4	25
41	Rates, determinants and success of implementing deprescribing in people with type 2 diabetes: A scoping review. Diabetic Medicine, 2021, 38, e14408.	1.2	24
42	Perceived medication adverse effects and coping strategies reported by chronic heart failure patients. International Journal of Clinical Practice, 2009, 63, 233-242.	0.8	23
43	Patientsâ€™ Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial. Drugs and Aging, 2019, 36, 1133-1139.	1.3	23
44	Variations in general practitionersâ€™ views of asthma management in four European countries. Social Science and Medicine, 2001, 53, 507-518.	1.8	21
45	A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. Pharmacoepidemiology and Drug Safety, 2010, 19, 319-334.	0.9	21
46	A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients. Health and Quality of Life Outcomes, 2011, 9, 83.	1.0	21
47	Pharmacy-based predictors of non-persistence with and non-adherence to statin treatment among patients on oral diabetes medication in the Netherlands. Current Medical Research and Opinion, 2018, 34, 1013-1019.	0.9	21
48	Perceived barriers for treatment of chronic heart failure in general practice; are they affecting performance?. BMC Family Practice, 2005, 6, 19.	2.9	20
49	The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus. British Journal of Clinical Pharmacology, 2006, 62, 660-665.	1.1	20
50	Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998â€“2004: a longitudinal observational study. Cardiovascular Diabetology, 2007, 6, 25.	2.7	20
51	Treatment of Uncomplicated Urinary Tract Infections: Exploring Differences in Adherence to Guidelines between Three European Countries. Annals of Pharmacotherapy, 2000, 34, 19-26.	0.9	19
52	Variations in asthma treatment in five European countries–judgement analysis of case simulations. Family Practice, 2002, 19, 452-460.	0.8	19
53	Physician, organisational and patient characteristics explaining the use of angiotensin converting enzyme inhibitors in heart failure treatment: a multilevel study. European Journal of Clinical Pharmacology, 2005, 61, 145-151.	0.8	19
54	Development and initial validation of prescribing quality indicators for patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 1876-1886.	0.4	19

#	Article	IF	Citations
55	Barriers and Enablers of Older Patients to Deprescribing of Cardiometabolic Medication: A Focus Group Study. Frontiers in Pharmacology, 2020, 11, 1268.	1.6	19
56	Precision medicine approaches for diabetic kidney disease: opportunities and challenges. Nephrology Dialysis Transplantation, 2021, 36, ii3-ii9.	0.4	19
57	Impact of clinical trials on the adoption of new drugs within a university hospital. European Journal of Clinical Pharmacology, 1991, 41, 325-328.	0.8	18
58	Influence of Elevated Cardiometabolic Risk Factor Levels on Treatment Changes in Type 2 Diabetes. Diabetes Care, 2008, 31, 501-503.	4.3	18
59	Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort. Nephrology Dialysis Transplantation, 2013, 28, 706-715.	0.4	18
60	Older peopleâ€™s attitudes towards deprescribing cardiometabolic medication. BMC Geriatrics, 2021, 21, 366.	1.1	18
61	Comparison of indicators assessing the quality of drug prescribing for asthma. Health Services Research, 2001, 36, 143-61.	1.0	18
62	Methods to identify the target population: implications for prescribing quality indicators. BMC Health Services Research, 2010, 10, 137.	0.9	17
63	Coping with adverse drug events in patients with heart failure: Exploring the role of medication beliefs and perceptions. Psychology and Health, 2012, 27, 570-587.	1.2	17
64	Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT database. BMJ Quality and Safety, 2013, 22, 339-347.	1.8	17
65	Application of the STOPP/START criteria to a medical record database. Pharmacoepidemiology and Drug Safety, 2017, 26, 1242-1247.	0.9	17
66	Predicting shortâ€•and longâ€•term glycated haemoglobin response after insulin initiation in patients with type 2 diabetes mellitus using machineâ€•learning algorithms. Diabetes, Obesity and Metabolism, 2019, 21, 2704-2711.	2.2	17
67	Limited effect of patient and disease characteristics on compliance with hospital antimicrobial guidelines. European Journal of Clinical Pharmacology, 2006, 62, 297-305.	0.8	16
68	Safety Communication Tools and Healthcare Professionalsâ€™ Awareness of Specific Drug Safety Issues in Europe: A Survey Study. Drug Safety, 2018, 41, 713-724.	1.4	16
69	A systematic review finds inconsistency in the measures used to estimate adherence and persistence to multiple cardiometabolic medications. Journal of Clinical Epidemiology, 2019, 108, 44-53.	2.4	16
70	Specialists' expectations regarding joint treatment guidelines for primary and secondary care. International Journal for Quality in Health Care, 2002, 14, 509-518.	0.9	15
71	Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000. Pharmacoepidemiology and Drug Safety, 2003, 12, 327-334.	0.9	15
72	Potential Overtreatment and Undertreatment of Diabetes in Different Patient Age Groups in Primary Care After the Introduction of Performance Measures. Diabetes Care, 2014, 37, 1312-1320.	4.3	15

#	Article	IF	Citations
73	Barriers and Enablers of Healthcare Providers to Deprescribe Cardiometabolic Medication in Older Patients: A Focus Group Study. Drugs and Aging, 2022, 39, 209-221.	1.3	15
74	Physiciansâ€™ attitudes towards treatment guidelines: differences between teaching and nonteaching hospitals. European Journal of Clinical Pharmacology, 2006, 62, 129-133.	0.8	14
75	Association Between Performance Measures and Glycemic Control Among Patients With Diabetes in a Community-wide Primary Care Cohort. Medical Care, 2013, 51, 172-179.	1.1	14
76	Understanding drug preferences, different perspectives. British Journal of Clinical Pharmacology, 2015, 79, 978-987.	1.1	14
77	Pharmacy-based predictors of non-adherence, non-persistence and reinitiation of antihypertensive drugs among patients on oral diabetes drugs in the Netherlands. PLoS ONE, 2019, 14, e0225390.	1.1	14
78	Effectiveness of a targeted and tailored pharmacistâ€led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: A cluster randomised controlled trial. British Journal of Clinical Pharmacology, 2021, 87, 2032-2042.	1.1	14
79	Does comorbidity explain trends in prescribing of newer antihypertensive agents?. Journal of Hypertension, 2004, 22, 2209-2215.	0.3	13
80	Claims in advertisements for antihypertensive drugs in a Dutch medical journal. Journal of Hypertension, 2007, 25, 713-722.	0.3	13
81	Identifying targets to improve treatment in type 2 diabetes; the Groningen Initiative to aNalyse Type 2 diabetes Treatment (GIANTT) observational study. Pharmacoepidemiology and Drug Safety, 2010, 19, 1078-1086.	0.9	13
82	Comparing Adverse Event Rates of Oral Blood Glucose-Lowering Drugs Reported by Patients and Healthcare Providers. Drug Safety, 2011, 34, 1191-1202.	1.4	13
83	Self-reported adverse drug events and the role of illness perception and medication beliefs in ambulatory heart failure patients: A cross-sectional survey. International Journal of Nursing Studies, 2011, 48, 1540-1550.	2.5	13
84	Cost-Effectiveness of Statins for Primary Prevention in Patients Newly Diagnosed with Type 2 Diabetes in The Netherlands. Value in Health, 2014, 17, 223-230.	0.1	13
85	HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups. Diabetes, Obesity and Metabolism, 2018, 20, 1957-1964.	2.2	13
86	Do Treatment Quality Indicators Predict Cardiovascular Outcomes in Patients with Diabetes?. PLoS ONE, 2013, 8, e78821.	1.1	13
87	GPs' treatment of uncomplicated urinary tract infections--a clinical judgement analysis in four European countries. Family Practice, 1999, 16, 605-607.	0.8	12
88	The effect of a patient-oriented treatment decision aid for risk factor management in patients with diabetes (PORTDA-diab): study protocol for a randomised controlled trial. Trials, 2012, 13, 219.	0.7	12
89	Identification of major cardiovascular events in patients with diabetes using primary care data. BMC Health Services Research, 2016, 16, 110.	0.9	12
90	Role of Patient and Practice Characteristics in Variance of Treatment Quality in Type 2 Diabetes between General Practices. PLoS ONE, 2016, 11, e0166012.	1.1	12

#	Article	IF	Citations
91	Drug expectations and drug choices of hospital physicians. Journal of Internal Medicine, 1993, 234, 155-163.	2.7	11
92	Inconsistent prescribing behaviour by physicians: Its effect on the validity of written case simulations. European Journal of General Practice, 1996, 2, 153-156.	0.9	11
93	Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study. Health and Quality of Life Outcomes, 2014, 12, 103.	1.0	11
94	The Role of Patientsâ€™ Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes. PLoS ONE, 2015, 10, e0139755.	1.1	11
95	'Thinking aloud' as a method of analysing the treatment decisions of physicians. European Journal of Public Health, 1994, 4, 55-59.	0.1	10
96	Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 1377-1383.	2.2	10
97	Modifiable Factors Associated with Non-adherence to Antihypertensive or Antihyperlipidemic Drugs Are Dissimilar: a Multicenter Study Among Patients with Diabetes in Indonesia. Journal of General Internal Medicine, 2020, 35, 2897-2906.	1.3	10
98	The Impact of Perceived Adverse Effects on Medication Changes in Heart Failure Patients. Journal of Cardiac Failure, 2010, 16, 135-141.e2.	0.7	9
99	Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design. Current Medical Research and Opinion, 2015, 31, 595-602.	0.9	9
100	Predictors of HbA1c levels in patients initiating metformin. Current Medical Research and Opinion, 2016, 32, 2021-2028.	0.9	9
101	Development and validation of prescribing quality indicators for patients with type 2 diabetes. International Journal of Clinical Practice, 2017, 71, e12922.	0.8	9
102	Development and Piloting of an Algorithm to Select Older Patients for Different Types of Medication Review. Frontiers in Pharmacology, 2019, 10, 217.	1.6	9
103	PRESCRIBING PATTERN IN A DUTCH UNIVERSITY HOSPITAL. Journal of Clinical Pharmacy and Therapeutics, 1991, 16, 423-433.	0.7	8
104	ASSESSMENT OF NEW CARDIOVASCULAR DRUGS. International Journal of Technology Assessment in Health Care, 2001, 17, 559-570.	0.2	8
105	Cardiometabolic treatment decisions in patients with type 2 diabetes: the role of repeated measurements and medication burden. BMJ Quality and Safety, 2010, 19, 411-415.	1.8	8
106	Representativeness of diabetes patients participating in a webâ€based adverse drug reaction monitoring system. Pharmacoepidemiology and Drug Safety, 2013, 22, 250-255.	0.9	8
107	The validity of a patient-reported adverse drug event questionnaire using different recall periods. Quality of Life Research, 2014, 23, 2439-2445.	1.5	8
108	Adherence to standard-dose or low-dose statin treatment and low-density lipoprotein cholesterol response in type 2 diabetes patients. Current Medical Research and Opinion, 2015, 31, 2197-2206.	0.9	8

#	Article	IF	Citations
109	Prescribing patterns, adherence and LDL-cholesterol response of type 2 diabetes patients initiating statin on low-dose versus standard-dose treatment: a descriptive study. International Journal of Clinical Practice, 2016, 70, 482-492.	0.8	8
110	Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care. Pharmacoepidemiology and Drug Safety, 2019, 28, 1175-1179.	0.9	8
111	A pilot qualitative study to explore stakeholder opinions regarding prescribing quality indicators. BMC Health Services Research, 2012, 12, 191.	0.9	7
112	Targeted and tailored pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: study protocol of a cluster randomised controlled trial. BMJ Open, 2020, 10, e034507.	0.8	7
113	Identifying patients at increased risk of hypoglycaemia in primary care: Development of a machine learningâ€based screening tool. Diabetes/Metabolism Research and Reviews, 2021, 37, e3426.	1.7	7
114	CONNECTING PRE-MARKETING CLINICAL RESEARCH AND MEDICAL PRACTICE. International Journal of Technology Assessment in Health Care, 2003, 19, 202-219.	0.2	6
115	Uptake of angiotensin II receptor blockers in the treatment of hypertension. European Journal of Clinical Pharmacology, 2005, 61, 461-466.	0.8	6
116	Process quality indicators for chronic kidney disease risk management: a systematic literature review. International Journal of Clinical Practice, 2016, 70, 861-869.	0.8	6
117	Prescribing Quality and Prediction of Clinical Outcomes in Patients With Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care, 2017, 40, e83-e84.	4.3	6
118	Views of general practice staff about the use of a patientâ€oriented treatment decision aid in shared decision making for patients with type 2 diabetes: A mixedâ€methods study. Health Expectations, 2018, 21, 64-74.	1.1	6
119	Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study. Drug Safety, 2019, 42, 881-886.	1.4	6
120	Non-LDL dyslipidemia is prevalent in the young and determined by lifestyle factors and age: The LifeLines cohort. Atherosclerosis, 2018, 274, 191-198.	0.4	5
121	No significant association of type 2 diabetesâ€related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives. Diabetes, Obesity and Metabolism, 2019, 21, 2267-2273.	2.2	5
122	Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands. Drug Safety, 2020, 43, 677-690.	1.4	5
123	Differences in Older Patients' Attitudes Toward Deprescribing at Contextual and Individual Level. Frontiers in Public Health, 2022, 10, 795043.	1.3	5
124	Is guideline-adherent prescribing associated with quality of life in patients with type 2 diabetes?. PLoS ONE, 2018, 13, e0202319.	1.1	4
125	When drug treatments bias genetic studies: Mediation and interaction. PLoS ONE, 2019, 14, e0221209.	1.1	4
126	Population-based screen-detected type 2 diabetes mellitus is associated with less need for insulin therapy after 10 years. BMJ Open Diabetes Research and Care, 2020, 8, e000949.	1.2	4

#	Article	IF	Citations
127	Trends in HbA 1c thresholds for initiation of hypoglycemic agents: Impact of changed recommendations for older and frail patients. Pharmacoepidemiology and Drug Safety, 2021, 30, 37-44.	0.9	4
128	Sex Differences in Lipid Profile across the Life Span in Patients with Type 2 Diabetes: A Primary Care-Based Study. Journal of Clinical Medicine, 2021, 10, 1775.	1.0	4
129	Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UK. Drug Safety, 2021, 44, 1073-1083.	1.4	4
130	Older Age, Polypharmacy, and Low Systolic Blood Pressure Are Associated With More Hypotension-Related Adverse Events in Patients With Type 2 Diabetes Treated With Antihypertensives. Frontiers in Pharmacology, 2021, 12, 728911.	1.6	4
131	Do we need individualised prescribing quality assessment? The case of diabetes treatment. International Journal of Clinical Pharmacy, 2011, 33, 145-149.	1.0	3
132	Development of a minimal set of prescribing quality indicators for diabetes management on a general practice level. Pharmacoepidemiology and Drug Safety, 2012, 21, 1053-1059.	0.9	3
133	Prescribing quality in secondary care patients with different stages of chronic kidney disease: a retrospective study in the Netherlands. BMJ Open, 2019, 9, e025784.	0.8	3
134	Type 2 diabetes patientsâ€™ views on prevention of hypoglycaemia â€“ a mixed methods study investigating self-management issues and self-identified causes of hypoglycaemia. BMC Family Practice, 2021, 22, 114.	2.9	3
135	Glycemic Control for Colorectal Cancer Survivors Compared to Those without Cancer in the Dutch Primary Care for Type 2 Diabetes: A Prospective Cohort Study. Cancers, 2021, 13, 2767.	1.7	3
136	Handling of New Drug Safety Information in the Dutch Hospital Setting: A Mixed Methods Approach. Drug Safety, 2022, , 1.	1.4	2
137	Emotional Distress is Associated with Lower Health-Related Quality of Life Among Patients with Diabetes Using Antihypertensive and/or Antihyperlipidemic Medications: A Multicenter Study in Indonesia. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1333-1342.	0.9	2
138	Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers. Frontiers in Pharmacology, 2022, 13, 786767.	1.6	2
139	Assessment of quality of prescribing using quality indicators. , 2016, , 433-442.		1
140	Changes in blood pressure thresholds for initiating antihypertensive medication in patients with diabetes: a repeated cross-sectional study focusing on the impact of age and frailty. BMJ Open, 2020, 10, e037694.	0.8	1
141	Process Evaluation of Implementing a Pharmacist-Led Intervention to Improve Adherence to Antihypertensive Drugs Among Patients with Type 2 Diabetes in Indonesian Community Health Centers. Frontiers in Pharmacology, 2021, 12, 652018.	1.6	1
142	Less Timely Initiation of Glucose-Lowering Medication Among Younger and Male Patients With Diabetes and Similar Initiation of Blood Pressure-Lowering Medication Across Age and Sex: Trends Between 2015 and 2020. Frontiers in Pharmacology, 2022, 13, .	1.6	1
143	Healthcare quality improvement programme improves monitoring of people with diabetes. Evidence-Based Healthcare and Public Health, 2004, 8, 122-124.	0.0	0
144	Healthcare quality improvement programme improves monitoring of people with diabetes*1. Evidence-Based Healthcare and Public Health, 2004, 8, 122-124.	0.0	0

#	Article	IF	Citations
145	PS12 - 60. Not all performance measures of diabetes management predict better glycemic control. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 140-141.	0.0	0
146	PS12 Contâ€™d - 62. Prescribing of aliskiren in practice: findings from the GIANTT diabetes. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 142-143.	0.0	0
147	PS3 - 5. Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes?. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 142-142.	0.0	0
148	PS14 - 2. Potential overtreatment and undertreatment of diabetes in primary care after the introduction of performance measures. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 175-175.	0.0	0
149	New renal guidelines; is more better?. Nephrology Dialysis Transplantation, 2014, 29, 720-721.	0.4	0
150	Older Age, Polypharmacy, and Low Systolic Blood Pressure Are Associated With More Hypotension-Related Adverse Events in Patients With Type 2 Diabetes Treated With Antihypertensives. Frontiers in Pharmacology, 2021, 12, 728911.	1.6	0